SimianX AI LogoSimianX AI

Record mula sa primary source

Decision-gradeTopline na resulta

Connect Biopharma nag-ulat ng Phase 3 topline results para sa rademikibart sa atopic dermatitis

Ang 8-K ay nagbubunyag ng topline results mula sa Phase 3 52-week study ng rademikibart sa moderate-to-severe atopic dermatitis na isinagawa ng partner na Simcere sa China. Isang hiwalay na Phase 1 IV pharmacology study topline ang inilabas din. Ang mga paglabas ng data na ito ay bumubuo sa regulatory/clinical milestone event.

Mahahalagang fact

Na-file
Mar 30, 2026, 11:06 AM
Kaganapan
Topline na resulta
Direksyon
Neutral
Kumpanya
CNTBConnect Biopharma
Asset
rademikibart
Pinagmulan
SEC 8-K
Kumpiyansa
May source
Pagpapabuti ng FEV1
250 mL kumpara sa 120 mL (130 mL na pagkakaiba, p=0.023)
Pagbawas ng pagbisita sa ED
50% kumpara sa placebo
Pagbawas ng kabiguan sa paggamot
66% kumpara sa placebo (p=0.153)

Sipi mula sa source

cntb-20260329 0001835268 false 0001835268 2026-03-29 2026-03-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2026 ________________________________________ Connect Biopharma Holdings Limited (Exact name of Registrant as Specified in Its Charter) ________________________________________ Cayman Islands 001-40212 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3580 Carmel Mountain Road , Suite 200 San Diego , California 92130 (Address of Principal Executive O

SEC 8-K

Higit pa tungkol sa asset na ito